A biomarker accessible in blood tests has been identified and validated. It could be used to predict which patients who have received stem cell transplants are at the highest risk for the potentially fatal immune response of graft-versus-host disease.
Treatment with magnetic resonance image-guided focused ultrasound (MRIgFU) ablation therapy significantly reduced pain in 67% of patients who received the treatment.
When patients with giant-cell tumor of the bone were treated with denosumab, which is a drug targeted against a protein that promotes bone destruction, the number of tumor giant cells decreased and new bone formation increased.
Scientists have identified a protein that makes some children and teenagers afflicted with Ewing sarcoma more resistant to chemotherapy.
The expression of the P16 protein, which inhibits cell growth, may be useful for predicting how osteosarcoma will respond to chemotherapy.
Childhood cancer survivors may need earlier colorectal cancer screening, especially if abdominal radiation was part of their treatment.
Drug Safety Communication on lenalidomide (Revlimid); FDA approval for pazopanib (Votrient)
Adding bisphosphonates to myeloma treatment decreases fractures of the vertebra and bone pain, affirm the results of a review of 20 trials.
Very early data are promising for a drug treatment for castration-resistant prostate cancer, with the agent showing particular effectiveness against tumors that have metastasized to the bone.
People who underwent cancer therapy as children have a heightened risk of developing gastrointestinal (GI) complications later in life, a new study shows.
